Journal Logo

Paul M. Vanhoutte Distinguished Lecture

Endothelial Function in the Time of the Giants

Heistad, Donald D MD

Author Information
Journal of Cardiovascular Pharmacology: November 2008 - Volume 52 - Issue 5 - p 385-392
doi: 10.1097/FJC.0b013e31818a403b
  • Free

Abstract

INTRODUCTION

This is a summary of the first Paul M. Vanhoutte Lecture at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics, April 2008. In the first part of this review, some of Dr. Vanhoutte's contributions will be described briefly.

In the second part of this review, I will describe some of our work. First, some vascular effects of serotonin, which are modulated by endothelium, will be summarized. Second, effects of hypercholesterolemia on the aortic valve, which has a unique endothelium, will be examined; the findings are timely because stenosis of the valve has emerged as an extremely important clinical problem. Third, some vascular effects of one of the superoxide dismutases (SOD), extracellular SOD (ecSOD), will be described. Vascular effects of a common human gene variant will be described, and a novel way to study gene variation will be illustrated.

PAUL M. VANHOUTTE

Dr. Vanhoutte is one of the fathers of vascular biology. He is a pioneer in what might be called translational endothelial biology. When Robert Furchgott discovered endothelium-derived relaxing factor (EDRF),1 Dr. Vanhoutte examined endothelial function in several disease states and thereby translated Furchgott's findings into pathophysiology as well as physiology.

Paul Michel Vanhoutte was born in Belgium and received a Doctor of Medicine, Surgery, and Obstetrics (equivalent of an MD) in Ghent, Belgium. He worked with Drs. Bouckaert and Leussen in Ghent, and he received an Aggregation in Higher Education (equivalent of a PhD) in Antwerp. He worked with Dr. John Shepherd in Rochester, Minnesota, and then he worked at the University of Antwerp, the Mayo Clinic, Baylor College of Medicine, and Servier Research Institute in Paris. Dr. Vanhoutte now is Director of the Biopharmceutical Development Center and Head of the Department of Pharmacology at the University of Hong Kong.

Dr. Vanhoutte organizes “Mechanisms of Vasodilatation” meetings, which bring together scientists who study vascular biology. When Furchgott and Zawadzki published abstracts in The Pharmacologist and Federation Proceedings that described release of EDRF by acetylcholine in 1979 and 1980, Dr. Vanhoutte invited Dr. Furchgott to present his work at a meeting in Wilrijk, Belgium, “Mechanisms of Vasodilation II.” When Furchgott described his finding, I did not appreciate the importance of the work. Because acetylcholine does not circulate in the blood, I though it was unlikely to reach the endothelium and release EDRF. Dr. Vanhoutte, Salvador Moncada, and other giants in endothelial biology were not as narrow in their thinking. They quickly demonstrated that endothelium releases EDRF in response to a wide variety of stimuli, including activated platelets and products released by platelets [including adenosine diphosphate (ADP) and serotonin].2-4

When talking about endothelial function, Dr. Vanhoutte starts his talks at “Mechanisms of Vasodilatation” and other meetings by acknowledging Furchgott's primacy in this area of research. I was, and am, impressed by Dr. Vanhoutte's faithfulness in attribution of discoveries to appropriate scientists.

Dr. Vanhoutte's ability to organize great meetings influenced the decision of the Nobel Committee in 1998. In 1986, at “Mechanisms of Vasodilatation V” in Rochester, Minnesota, Furchgott and Ignarro presented evidence that nitric oxide is EDRF. That meeting proved to be crucial, as acknowledged by Professor Sten Lindahl, when Furchgott, Ignarro, and Murad received the Nobel Prize for “Nitric Oxide as a Signaling Molecule in the Cardiovascular System” in 1998 (Figure 1).

FIGURE 1
FIGURE 1:
Presentation speech by Professor Lindahl at award of the Nobel Prize in Physiology or Medicine, Stockholm, 1998.

Paul Vanhoutte is an amazingly prolific investigator in endothelial biology and other areas of vascular biology. He is a truly extraordinary mentor and has trained over 100 fellows (Table 1). Dr. Vanhoutte's trainees, several of whom are also international leaders in cardiovascular research, continue to seek his advice as an “academic father.”

TABLE 1
TABLE 1:
Fellows of Paul M. Vanhoutte

VASCULAR EFFECTS OF SEROTONIN

The remainder of this review will focus on some of our work. I apologize to other authors about failing to refer to their work because of limitations in the number of references.

Because of Henry and Yokoyama's finding5 that vasoconstrictor responses to serotonin are augmented in atherosclerotic vessels ex vivo, we tested the hypothesis that vasoconstrictor responses to serotonin in vivo are exaggerated by atherosclerosis. We found that atherosclerosis produces enormous potentiation of vasoconstrictor responses to serotonin in the large arteries of hind limb of monkeys.6 We also found that serotonin, which produces minimal constriction of retinal arteries in monkeys, produces choroidal and retinal vasospasm in atherosclerotic monkeys (Figure 2)7 and a profound reduction in ocular blood flow, accompanied by transient flattening of the electroretinogram.8 We suggested that transient ischemic attacks (TIAs), which are characterized by both transient cerebral ischemia and transient blindness, may be mediated by vasospasm initiated by release of serotonin from platelets.7,8

FIGURE 2
FIGURE 2:
Fluorescein angiograms in 2 atherosclerotic monkeys under control conditions (left panels) and during infusion of serotonin IV (right panels). In one monkey, serotonin produced spasm of the 2 choroidal arteries and abolished blood flow to the choroid (upper right panel). In another monkey, serotonin produced spasm of the retinal artery and 1 choroidal artery (lower right panel).From Hayreh SS, Piegors DJ, Heistad DD. Serotonin-induced constriction in ocular arteries in atherosclerotic monkeys: Implications for ischemic disorders of the retina and optic nerve head. Arch Ophthalmol. 1997;115:220-228 . Copyright © 1997 American Medical Association. Used with permission.

What is the mechanism of hyperresponsiveness to serotonin in atherosclerotic vessels? Vanhoutte and his colleagues had shown that vascular responses to serotonin are modulated by endothelium.3,4 They found that, when endothelium is normal, serotonin releases EDRF (nitric oxide) and produces vascular relaxation. In contrast, Vanhoutte found that serotonin contracts blood vessels when endothelium is removed or dysfunctional. We wondered whether potentiation of vasoconstrictor responses to serotonin in atherosclerotic arteries might be mediated by impairment of endothelial function. This question led us to examine endothelial function in atherosclerotic arteries, and the finding that atherosclerosis profoundly impairs endothelial function.9 I should acknowledge that the hyperresponsiveness to serotonin that we observed in the limb, retinal vessels, and other vascular beds turned out to be mediated by other mechanisms, in addition to endothelial dysfunction.

Why is hyperresponsiveness to serotonin important in atherosclerosis? Aggregation of platelets releases several vasoactive substances, including serotonin, ADP, and thromboxane. Vanhoutte showed that endothelium modulates vascular responses to activation of platelets,2 so that relaxation to activation of platelets ex vivo is impaired or even changes to contraction when endothelium is removed. Importantly, he also showed that, in the presence of several disease states (hypertension, diabetes, etc.) vascular responses to activation of platelets are altered profoundly.

Because of Vanhoutte's findings in blood vessels ex vivo, Dr. Sanjay Kaul examined vascular responses to activation of platelets in vivo. We found that vasodilator responses to activation of platelets are profoundly impaired by atherosclerosis.10-12 This led us and others, including Vanhoutte3 and Willerson,13 to speculate that endothelial dysfunction may contribute to susceptibility of atherosclerotic vessels to vasospasm.

Many of our experiments, as well as those of others, have focused on the role of endothelium in modulation of vasomotor responses in large (conduit) arteries. We then initiated experiments to examine endothelial function in small (resistance) vessels by studying modulation of resistance in monkeys. Responses to acetylcholine were examined in the perfused hindlimb of monkeys. A nitric oxide synthase (NOS) inhibitor was given to demonstrate (presumably) that reduction in resistance in response to acetylcholine is blocked by NG-monomethyl-L-arginine (L-NMMA) and thus mediated by NOS. To our great surprise, we could not attenuate vasodilator responses to acetylcholine by administration of L-NMMA in 2 monkeys (unpublished data).

We then pursued this mechanism in the hindlimb of normal rabbits and arrived at the same conclusion.14 Although NOS inhibitors increased basal resistance, which is mediated by NO, in the limb, NOS inhibitors did not attenuate dilator responses of resistance vessels to acetylcholine. We did not pursue the mechanism further, but we assume that an endothelium-derived hyperpolarizing factor (EDHF), as extensively studied by Vanhoutte15 and several other investigators, contributes importantly to dilator responses of resistance vessels to acetylcholine. If, in some vascular beds, EDHF (or several EDHFs) mediate decreases in vascular resistance to endothelium-dependent agonists, EDHFs are of great importance in physiology and pathophysiology. EDHF is now a major focus of “Mechanisms of Vasodilatation” meetings, which Vanhoutte organizes.

We have suggested that there is a stereotypical pattern of vascular changes in atherosclerosis and hypertension. We proposed that there is a sick vessel syndrome,16 the hallmarks of which are endothelial dysfunction, relative preservation of relaxation of vascular muscle, exaggerated vasoconstrictor responses (especially to serotonin), and structural changes that are generally adaptive and protective. In our experience with a variety of disease states, hyperresponsiveness to serotonin, which is typically far greater in magnitude than endothelial dysfunction, is the most consistent marker of vascular disease.

A key question related to potential benefits of treatment of hypercholesterolemia is whether atherosclerotic lesions can regress with reabsorption of lipid from arteries and improvement of endothelial function. The question was answered many years ago, in monkeys first17-20 and then in patients.21,22 In contrast to an enormous reduction in myocardial infarction and stroke during reduction of plasma cholesterol, it was surprising to fine that structural changes of arteries (as measured by luminal diameter or intimal/medial area) improve only minimally.22 The explanation for this paradox is that collagen increases in the artery as lipid and inflammatory cells leave the atherosclerotic artery so that intimal/medial area is reduced only slightly and increases in luminal diameter are limited. The vulnerable plaque becomes more stable (and less likely to rupture and produce arterial thrombosis), however, as arterial lipid and inflammation decrease and collagen increases.23

Although structural improvement of arteries (as measured by intimal/medial area) is modest during regression of atherosclerosis, there is striking improvement in function in the arteries. We found in monkeys that endothelial function improves rapidly during treatment of hypercholesterolemia.18 The finding was confirmed in humans.21 In addition, hyperresponsiveness to serotonin subsides very rapidly during treatment of hypercholesterolemia and regression of atherosclerosis.24

Generation of superoxide in the arterial wall, with inactivation of nitric oxide, contributes importantly to endothelial dysfunction in atherosclerosis. Furthermore, improvement of endothelial function during regression of atherosclerosis is accompanied by (and presumably mediated by) reduction of vascular superoxide.25 These findings support the concept that oxidative stress plays a key role in the pathophysiology of atherosclerosis.

AORTIC VALVULAR STENOSIS

Endothelium of the aortic and other cardiac valves is subjected to unusual flow dynamics. Blood is ejected rapidly past endothelium on the ventricular side of the valve. When the valve closes during diastole, endothelium on the aortic side of the valve is exposed to turbulent (or disordered) blood flow. A striking finding is that endothelium of the aortic valve maintains a unique phenotype in vitro.26 During flow in vitro, aortic endothelium aligns in the direction of flow, but aortic valvular endothelium aligns perpendicular to flow (Figure 3).

FIGURE 3
FIGURE 3:
Alignment of porcine aortic endothelial cells (left) and porcine aortic valve endothelial cells (right) during flow in vitro. Aortic cells align parallel to flow, and aortic valvular cells align perpendicular to flow.Butcher JT, Penrod AM, García AJ, Nerem RM. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arterioscler Thromb Vasc Biol 2004;24:1429-1434 . Copyright © 2004 American Heart Association. Used with permission.

The pathophysiology of aortic valvular stenosis is of interest because it is an enormously important clinical problem and because risk factors and histopathology suggest a close relationship to atherosclerosis.27 Risk factors include older age, hypercholesterolemia, male sex, smoking, and hypertension. Stenotic aortic valves resemble atherosclerotic lesions, with calcification, lipid deposition, inflammation, and matrix remodeling.

We stumbled upon the first experimental model of aortic valvular stenosis when we obtained “Reversa” mice from Dr. Stephen Young.28 The mice are lipoprotein receptor- deficient (LDLr-/-) and apolipoprotein B-100 only (ApoB100/100), which increases susceptibility to atherosclerosis. When some mice became too old to study as part of a protocol to examine endothelial function, we chose to determine whether superoxide is increased in the aortic valve. The rationale was that reactive oxygen species (ROS) are increased in atherosclerosis, and ROS might also be increased in the aortic valve of atherosclerotic mice. We found a striking increase in superoxide in the aortic valve of LDLr-/-ApoB100/100 mice (Figure 4).

FIGURE 4
FIGURE 4:
Dihydroethidium fluorescence in aortic valve and aorta from a normal mouse (left) and a hypercholesterolemic mouse with aortic stenosis (right). Increased fluorescence indicates an increase in superoxide.From Weiss RM, Ohashi M, Miller JD, et al. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114:2065-2069 . Copyright © 2006 American Heart Association. Used with permission.

Dr. Robert Weiss then used echocardiographic imaging and microtransducer-tipped catheters to determine whether there was evidence of aortic valvular stenosis in these mice.29 About one third of 20-month- old LDLr-/-ApoB100/100 mice had severe aortic stenosis, with an estimated 75% reduction in valve area, left ventricular hypertrophy, and a 35 to 70 mm Hg peak pressure gradient across the aortic valve. We were delighted to have discovered the first experimental animals with spontaneous development of the full syndrome of aortic valvular heart disease.

We have pursued these findings in humans. Dr. Jordan Miller tested the hypothesis that oxidative stress is increased in calcified aortic valves in humans and examined mechanisms that increase or protect against oxidative stress in the valves.30 He found that, in normal aortic valves (from human hearts that were not suitable for transplantation), superoxide levels are low and homogenous throughout the valve. In stenotic valves (removed during surgical replacement of the valve), superoxide was normal in noncalcified regions and increased 2-fold near calcified regions of the valve. Thus, oxidative stress is increased in calcified regions of stenotic aortic valves. Dr. Francisco Laurindo also has found oxidative stress in aortic valves obtained from humans at surgery or autopsy.31

Mechanisms responsible for oxidative stress in the aortic valve were a surprise to us because they differ from mechanisms observed previously in atherosclerotic arteries. In atherosclerotic plaques, upregulation of NAD(P)H oxidase plays a key role in increasing oxidative stress, and expression of antioxidant enzymes (including SODs) is generally unchanged or increased.32 In contrast, we found in stenotic aortic valves from humans that NAD(P)H oxidase activity is not increased, nitric oxide synthase may be uncoupled, and SOD activity is decreased. In addition, levels of hydrogen peroxide are markedly elevated in calcified regions of stenotic valves, and catalase expression is reduced.30 Thus, there appear to be fundamental differences in mechanisms that account for increased oxidative stress in atherosclerotic arteries and in stenotic aortic valves.

A key question is whether increases in oxidative stress contribute to development of valvular calcification or whether oxidative stress is a consequence of valvular stenosis. The answer to this question is not known, but there are many proteins and transcription factors in blood vessels that are redox-sensitive (Table 2). We are intrigued by the possibility that increases in reactive oxygen species in the aortic valve may play an important role in the pathophysiology of aortic valvular calcification by initiating signaling of procalcific pathways.

TABLE 2
TABLE 2:
Some Proteins/Transcription Factors in Vascular Tissue That are Positively Regulated by Oxidative Stress

If pharmacological approaches can be demonstrated to slow or stop the progression of aortic valvular stenosis, one might avoid surgical replacement of the valve. Retrospective studies suggest that HMGCoA-reductase inhibitors (ie, statins) and angiotensin-converting enzyme inhibitors may slow the progression of stenosis of the aortic valve. Prospective studies of angiotensin-converting enzyme inhibitors have failed to show slowing of progression of stenosis, and studies of statins have provided conflicting results.33,34 Results of randomized trails are not yet available. We are concerned that ongoing randomized trials are using statins in patients with moderately severe stenosis. We speculate that statins may not be effective at this advanced stage of stenosis and may be much more effective in slowing progression of aortic stenosis when given very early in the process.

“Reversa” mice have a conditional allele of the gene encoding for microsomal triglyceride transfer protein (MTTP) and inducible Mx1-Cre transgene.28 After induction of Cre expression with polyinosinic-polycytidylic acid, the genetic “switch” deletes the MTTP gene, and hypercholesterolemia in the mice decreases quickly to normal levels. Our preliminary evidence suggests that reduction of hypercholesterolemia at an early stage may result in removal of lipid from the aortic valve and abrogate the development of aortic valvular stenosis.35

VASCULAR EFFECTS OF AN SOD GENE VARIANT

Oxidative stress and antioxidant mechanisms are of great interest in vascular biology. We are especially interested in the role of extracellular SOD (ecSOD), because ecSOD is highly expressed in blood vessels, protects against inactivation of nitric oxide,36 and thereby helps to preserve endothelial function.

Several years ago, Dr. Yi Chu demonstrated that gene transfer of ecSOD improves endothelial function in spontaneously hypertensive mice (SHR) and reduces arterial pressure.37 Of particular interest was the finding that beneficial effects of ecSOD require the heparin-binding domain (HBD), which mediates binding of ecSOD to heparan sulfate proteoglycans on cell surfaces.

There is a gene variant, R213G, in the HBD of ecSOD, which is common (about 2 to 5% of the population) in humans. A large association study demonstrated increased risk of ischemic heart disease in heterozygotes carrying ecSODR213G.38 The ecSODR213G gene variant does not reduce enzymatic activity of ecSOD, but binding to endothelia cells is impaired. Thus, one might predict that the ecSODR213G gene variant would lead to increased susceptibility to oxidative stress and endothelial dysfunction.

Yi Chu constructed an adenovirus that expresses ecSODR213G to examine vascular effects of the gene variant.39 Studies of gene variants are of great interest, as Science described human genetic variation as the Breakthrough of the Year for 2007. In addition to studies to determine which gene variants cause human disease, a major goal is to determine how gene variants produce disease. We have developed a method, using adenoviral gene transfer, to study a gene variant (or mutant). This method complements studies of human phenotype of gene variants, and studies of knock-out and knock-in transgenic mice.

We examined vascular effects of ecSODR213G and normal ecSOD. Our goal was to determine whether gene transfer of ecSODR213G has less beneficial effect than normal ecSOD on vasomotor function and arterial pressure in SHR. Recombinant adenoviruses were injected intravenously. Adenoviruses are removed in the liver, and we anticipated that, after infection of hepatocytes, ecSODR213G and normal ecSOD proteins would be produced in the liver, released into the circulation, and bound by endothelial cells.

In a previous study,37 we found that gene transfer of normal ecSOD reduces arterial pressure and superoxide in the aorta and improves endothelial function in SHR. Binding to endothelial cells and blood vessels was much less by ecSODR213G than by normal ecSOD. The novel finding was that ecSODR213G, in contrast to normal ecSOD, has no significant protective effect on arterial pressure, vasomotor function, or vascular superoxide in SHR (Figure 5). Its binding to endothelial cells (in vessels) was greatly impaired.39

FIGURE 5
FIGURE 5:
Effects of gene transfer of ecSODR213G in spontaneous hypertensive rats (SHR) on superoxide in aorta (left panel), systolic pressure (middle panel), and relaxation of carotid artery to acetylcholine (right panel). Values are compared to normotensive Wistar-Kyoto (WKY) rats. * P < 0.05 versus Control. Adapted from Chu Y, Alwahdani A, Iida S, et al. Vascular effects of human extracellular superoxide dismutase R213G variant. Circulation. 2005;112:1047-1053 .

We have also observed that normal ecSOD, but not ecSODR213G, protects against endothelial dysfunction in rats with heart failure40 and in mice with inflammation produced by bacterial endotoxin.41 The findings provide a possible mechanism by which humans with ecSODR213G are predisposed to vascular disease.

CLOSING

In addition to being a great scientist and mentor, Paul Vanhoutte is a wonderful friend to many people. His studies of blood vessels ex vivo have inspired many of our studies. It was a great honor and privilege to give the first Paul M. Vanhoutte Lecture in 2008.

I have been fortunate to have many scientists work in my laboratory during the past 30 years. The opportunity to work with these young people, and to get to know them and their families, is a great joy and one of the most satisfying experiences of my life.

Thanks to: Michael Welsh, Samuel Sandberg, Shirley Mueller, Paul Gross, Seizo Sadoshima, David Busija, Jacque Gourley, Bruce Brown, Gary Baumbach, Charles Haws, David Barry, Andrew Werber, Kinya Tamaki, William Mayhan, Douglas Wysham, David Wagner, Peter Coyle, Frank Faraci, Lori Panther, Charles Ayres, J. Koudy Williams, J. Antonio G. Lopez, Roberto Castro, Kimberly Schalk, John Williams, Keith Kadel, Mazen Maktabi, Shuh-Tsong Yang, William Farrell, Jon Siems, James Choi, Michael Thebert, Michael Hajdu, Kenichiro Fujii, Frederick Hurley, Andreas Mügge, Margaret Murray, Barbara Weno, Conrad Bauknight, Ricardo Vasquez, Sanjay Kaul, Richard Padgett, Takanari Kitazono, Roberto Paterno, Claudio Napoli, Steve Ryan, Keith Benzuly, Hisao Taguchi, Johnny E. Brian, Jr., John Diana, Jr., Christopher Sobey, Monica Bhopatkar, C. David Rios, Srinivas Bonthu, Hiroaki Ooboshi, Donald Lund, Markus Lang, Stuart Christensen Yi Chu, D. Dean Potter, Kazunori Toyoda, Kristy Lake, Carol Gunnett, Hiroshi Nakane, Kevin Belasco, Jon Andresen, Chris Hathaway, Suneer Jain, Clifford Fulton, Yoshimasa Watanabe, Pragnesh Patel, Abdullah Alwahdani, Tzung K. Hsiai, Masuo Ohashi, Yasafumi Nakajima, Shinichiro Iida, Jiro Kitayama, Jordan Miller, Jung Hyun Choi, Yoshinobu Wakisaka, Saul Wilson, Ricardo Peña-Silva, and Kristine Serrano.

REFERENCES

1. Furchgott FR, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
2. Cohen R, Shepherd J, Vanhoutte P. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science. 1983;221:173-174.
3. Vanhoutte PM, Houston DS. Platelets, endothelium, and vasospasm. Circulation. 1985;72:728-734.
4. Houston DS, Shepherd JT, Vanhoutte PM. Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. J Clin Invest. 1986;78:539-544.
5. Henry PD, Yokoyama M. Supersensitivity of atherosclerotic rabbit aorta to ergonovine: Mediation by a serotonergic mechanism. J Clin Invest. 1980;66:306-313.
6. Heistad DD, Armstrong ML, Marcus ML, et al. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res. 1984;54:711-718.
7. Hayreh SS, Piegors DJ, Heistad DD. Serotonin-induced constriction in ocular arteries in atherosclerotic monkeys: Implications for ischemic disorders of the retina and optic nerve head. Arch Ophthalmol. 1997;115:220-228.
8. Williams JK, Baumbach GL Armstrong ML, Heistad D. Hypothesis: vasoconstriction contributes to amaurosis fugax. J Cereb Blood Flow Metab. 1989;9:111-116.
9. Freiman PC, Mitchell GG, Heistad DD, et al. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res. 1986;58:783-789.
10. Kaul S, Heistad DD, Mügge A, et al. Vascular responses to platelet activation in normal and atherosclerotic primates in vivo. Arterioscler Thromb. 1991;11:1745-1751.
11. Kaul S, Padgett RC, Waack BJ, et al. Effect of atherosclerosis on responses of the perfused rabbit carotid artery to human platelets. Arterioscleros Thromb. 1992;12:1206-1213.
12. Kaul S, Waack BJ, Padgett RC, et al. Altered vascular responses to platelets from hypercholesterolemic humans. Circ Res. 1993;72:737-743.
13. Willerson J, Hillis M, Winniford M, Buja L. Speculation regarding mechanisms responsible for acute ischemic heart disease syndrome. J Am Coll Cardiol. 1986;8:245-250.
14. Mügge A, Lopez JAG, Piegors DJ, et al. Acetylcholine-induced vasodilation in the rabbit hindlimb is not inhibited by analogues of L-arginine. Am J Physiol Heart Circ Physiol. 1991;29:H242-H247.
15. Félétou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol. 2006;26:1215-1225.
16. Heistad DD, Armstrong ML. Sick vessel syndrome: Can atherosclerotic arteries recover? Circulation. 1994;89:2447-2450.
17. Armstrong ML, Warner E, Conner W. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27:59-67.
18. Harrison DG, Armstrong ML, Freiman PC, et al. Restoration of endothelium dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
19. Armstrong ML, Heistad DD, Marcus ML, et al. Hemodynamic sequelae of regression of experimental atherosclerosis. J Clin Invest. 1983;71:104-113.
20. Heistad DD, Mark AL, Marcus ML, et al. Dietary treatment of atherosclerosis abolishes hyperresponsiveness to serotonin: Implications for vasospasm. Circ Res. 1987;61:346-351.
21. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet. 1993;341:1496-1500.
22. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
23. Levine GN, Keaney JFJ, Vita JA. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512-521.
24. Benzuly KH, Padgett RC, Kaul S, et al. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994;89:1810-1818.
25. Hathaway C, Heistad DD, Piegors DJ, Miller FM. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res. 2002;90:277-283.
26. Butcher JT, Penrod AM, García AJ, et al. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arterioscler Thromb Vasc Biol. 2004;24:1429-1434.
27. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316-3326.
28. Lieu HD, Withycombe SK, Walker Q, et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation. 2003;107:1315-1321.
29. Weiss RM, Ohashi M, Miller JD, et al. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114:2065-2069.
30. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pe~na-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Amer Coll Cardiol. 2008, in press.
31. Liberman M, Bassi E, Martinatti Mk, et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol. 2008;28:463-470.
32. Fukai T, Galis ZS, Meng XP, et al. Vascular expression of extracellular superoxide dismutase in atherosclerosis. J Clin Invest. 1998;101:2101-2111.
33. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
34. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-561.
35. Miller JD, Berry CJ, Serrano KM, et al. Effects of normalizing hyperlipidemia on oxidative stress and disease progression in a mouse model of aortic valve stenosis [abstract]. Circulation. 2007;116:Ii-52.
36. Oury TD, Day BJ, Crapo JD. Extracellular superoxide dismutase: A regulator of nitric oxide bioavailability. Lab Invest. 1996;75:617-636.
37. Chu Y, Iida S, Lund DD, et al. Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: Role of heparin binding domain. Circ Res. 2003;92:461-468.
38. Juul K, Tybjaerg-Hansen A, Marklund S, et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation. 2004;109:59-65.
39. Chu Y, Alwahdani A, Iida S, et al. Vascular effects of human extracellular superoxide dismutase R213G variant. Circulation. 2005;112:1047-1053.
40. Iida S, Chu Y, Weiss RM, et al. Vascular Effects of a common gene variant of extracellular superoxide dismutase in heart failure. Am J Physiol Heart. 2006;291:H914-920.
41. Lund DD, Chu Y, Brooks RM, et al. Effects of a common human gene variant of Ecsod on endothelial function after endotoxin in mice. J Physiol (London). 2007;584:583-590.
Keywords:

endothelium; serotonin; aortic valve; oxidative stress

© 2008 Lippincott Williams & Wilkins, Inc.